77 related articles for article (PubMed ID: 9496896)
1. Comment on the article "Analysis of the incidence of solid cancer among atomic bomb survivors using a two-stage model of carcinogenesis" by M. Kai, E. G. Luebeck and S. H. Moolgavkar (Radiat. Res. 148, 348-358, 1997).
Sherman CD
Radiat Res; 1998 Mar; 149(3):308-9. PubMed ID: 9496896
[No Abstract] [Full Text] [Related]
2. Comments on the article "Studies of the mortality of atomic bomb survivors. Report 12, part I. Cancer: 1950-1990" by D. A. Pierce, Y. Shimizu. D. L. Preston, M. Vaeth and K. Mabuchi (Radiat. Res. 146, 1-27, 1996).
Little MP
Radiat Res; 1997 Oct; 148(4):399-401. PubMed ID: 9339957
[No Abstract] [Full Text] [Related]
3. Comment on "Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987. Evaluation of radiation-related risk" by Land et al. (Radiat. Res. 146, 28-36, 1996).
Pogoda JM; Preston-Martin S
Radiat Res; 1996 Sep; 146(3):356. PubMed ID: 8752317
[No Abstract] [Full Text] [Related]
4. Cancer and non-cancer effects in Japanese atomic bomb survivors.
Little MP
J Radiol Prot; 2009 Jun; 29(2A):A43-59. PubMed ID: 19454804
[TBL] [Abstract][Full Text] [Related]
5. Understanding estimation of time and age effect-modification of radiation-induced cancer risks among atomic-bomb survivors.
Lagarde F
Health Phys; 2006 Dec; 91(6):608-18. PubMed ID: 17099404
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of lung tumour mortality risk in the Japanese A-bomb survivors and in the Colorado Plateau uranium miners: support for the ICRP lung model.
Little MP
Int J Radiat Biol; 2002 Mar; 78(3):145-63. PubMed ID: 11869470
[TBL] [Abstract][Full Text] [Related]
7. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
[TBL] [Abstract][Full Text] [Related]
8. More about cancer incidence in atomic bomb survivors: solid tumors, 1958-1987.
Ron E; Preston DL; Mabuchi K
Radiat Res; 1995 Jan; 141(1):126-7. PubMed ID: 7997509
[No Abstract] [Full Text] [Related]
9. Age-time patterns for cancer and noncancer excess risks in the atomic bomb survivors.
Preston DL; Pierce DA; Shimizu Y
Radiat Res; 2000 Dec; 154(6):733-4;discussion 734-5. PubMed ID: 11187021
[No Abstract] [Full Text] [Related]
10. Effects of radiation on incidence of primary liver cancer among atomic bomb survivors.
Cologne JB; Tokuoka S; Beebe GW; Fukuhara T; Mabuchi K
Radiat Res; 1999 Oct; 152(4):364-73. PubMed ID: 10477913
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the risks of cancer incidence and mortality following radiation therapy for benign and malignant disease with the cancer risks observed in the Japanese A-bomb survivors.
Little MP
Int J Radiat Biol; 2001 Apr; 77(4):431-64. PubMed ID: 11304437
[TBL] [Abstract][Full Text] [Related]
12. Male breast cancer incidence among atomic bomb survivors.
Ron E; Ikeda T; Preston DL; Tokuoka S
J Natl Cancer Inst; 2005 Apr; 97(8):603-5. PubMed ID: 15840883
[TBL] [Abstract][Full Text] [Related]
13. Re: solid cancer incidence in atomic bomb survivors exposed in utero or as young children.
Richardson DB; Wing S
J Natl Cancer Inst; 2008 Oct; 100(20):1482-3. PubMed ID: 18840820
[No Abstract] [Full Text] [Related]
14. Response to the letter of Sheldon Wolff (Radiat. Res. 141, 230-231, 1995).
Ron E; Preston DL; Mabuchi K
Radiat Res; 1995 Jul; 143(1):116-7. PubMed ID: 7639847
[No Abstract] [Full Text] [Related]
15. The LSS Cohort of Atomic Bomb Survivors and LNT. Comments on ''Solid Cancer Incidence among the Life Span Study of Atomic Bomb Survivors: 1958-2009" (Radiat Res 2017; 187:513-37) and "Reply to the Comments by Mortazavi and Doss" (Radiat Res 2017; 188:369-71).
Siegel JA; Sacks B; Socol Y
Radiat Res; 2017 Oct; 188(4):463-464. PubMed ID: 28991523
[No Abstract] [Full Text] [Related]
16. [Diagnostic radiation and the risk of cancer].
Kai M
Gan To Kagaku Ryoho; 2005 Sep; 32(9):1229-34. PubMed ID: 16184914
[TBL] [Abstract][Full Text] [Related]
17. Comments on the hazard function of a two-stage carcinogenesis model.
Zheng Q
Radiat Res; 1999 Jan; 151(1):120-1. PubMed ID: 9973091
[No Abstract] [Full Text] [Related]
18. Are two mutations sufficient to cause cancer? Some generalizations of the two-mutation model of carcinogenesis of Moolgavkar, Venzon, and Knudson, and of the multistage model of Armitage and Doll.
Little MP
Biometrics; 1995 Dec; 51(4):1278-91. PubMed ID: 8589222
[TBL] [Abstract][Full Text] [Related]
19. Comments on 'Alternatives to the BEIR relative risk model for explaining atomic bomb survivor cancer mortality'.
Nambi KS; Soman SD
Health Phys; 1988 Sep; 55(3):579-80. PubMed ID: 3170213
[No Abstract] [Full Text] [Related]
20. Individual variation of somatic gene mutability in relation to cancer susceptibility: prospective study on erythrocyte glycophorin a gene mutations of atomic bomb survivors.
Kyoizumi S; Kusunoki Y; Hayashi T; Hakoda M; Cologne JB; Nakachi K
Cancer Res; 2005 Jun; 65(12):5462-9. PubMed ID: 15958596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
